Pulmatrix Corporation (PULM): Price-to-Sales Ratio

Corporate company logo of Pulmatrix Inc (PULM)

Pulmatrix, Inc. (PULM) faces risks regarding the approval of the iSPERSE platform and a rapid cash burn rate. The company's price/sales multiple reflects market expectations, where 46.50 serves as the final level marker. Development efforts target the treatment of COPD through targeted drug delivery. A compact team of scientists is incentivized by stock options, while complex trials have been outsourced to third-party contractors to optimize processes.

Price-to-Revenue Ratio: pulmatrix.com (PULM) for 07/04/2022 - 10/16/2025

Analytical breakdowns for Pulmatrix Corp (PULM)

- share price and consensus valuation forecast:
Price Performance Chart pulmatrix.com|PULM - Price Target Chart
- stock exchange capitalization data:
Market Valuation Pulmatrix Corp|PULM - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Pulmatrix|PULM - Company Book Value|Market Value to Book Value Ratio pulmatrix.com|PULM - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Pulmatrix, Inc.|PULM - Long-Term Debt to Capital|Short-Term Debt to Capital Pulmatrix Corporation|PULM - Company Total Debt|Debt to Book Capital Pulmatrix Corp|PULM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pulmatrix|Interim Coverage Ratio pulmatrix.com
- company profitability and valuation multiples indicators:
PULM - Net Income|Net Profit Forecast Pulmatrix, Inc.|PULM - Price to Earnings Ratio|Future Price to Earnings Multiple Pulmatrix Inc|PULM - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pulmatrix Corp|PULM - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Pulmatrix|PULM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months pulmatrix.com|PULM - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Pulmatrix, Inc.
- total revenue and sales volume data:
PULM - Company Revenue|Company Expected Revenue pulmatrix.com|PULM - Market Cap to Revenue|Forward P/S Multiple Pulmatrix Corp
Summary company analytics:pulmatrix.com
Original product of Pulmatrix Corp

The P/S multiple determines the market value of a company relative to its total revenue, measuring capitalization per unit of sales. For Pulmatrix, Inc. (PULM), this metric reflects the market's valuation of the iSPERSE technology's potential and partnerships with pharmaceutical behemoths in the field of inhalation therapy. By analyzing the price-to-sales chart, an investor can identify if the asset is overbought or find an optimal entry point. This metric allows for balancing the risk of overpayment against the fundamental growth prospects of the business.

Competitors of Pulmatrix, Inc.

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|MENS: Market Cap to Revenue|LGND - P/S Multiple|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|PRGO (perrigo.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alvotech SA|Market Cap to Revenue Liquidia Corp (LQDA)|P/S Multiple GLPG|P/S Multiple ANI Pharmaceuticals Corp (ANIP)|MannKind Corporation - Market Cap to Revenue|Market Cap to Sales Volume AMPH (amphastar.com)|PCRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S Multiple|AQST - Price-to-Revenue Coefficient|Market Cap to Revenue SCPH|Market Cap to Revenue Ratio TECX (Tectonic)|Market Cap to Revenue TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Price-to-Revenue Coefficient BioHarvest Sciences Inc (BHST)|EXOZ - Price-to-Revenue Ratio|ORMP (Oramed Pharmaceuticals) - Market Cap to Revenue Ratio|ENTX: P/S Multiple|Market Cap to Revenue MindWalk Holdings, Inc.|Market Cap to Revenue ABVC|Cumberland Corp (CPIX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Quantum BioPharma Ltd (QNTM)|FGEN: Price-to-Sales Ratio|Telomir Pharmaceuticals, Inc. - Market Cap to Revenue|P/S Multiple Rani Therapeutics Holdings RANI|SNYR - Price-to-Revenue Ratio|RLYB: Price-to-Revenue Ratio|lexariabioscience.com (LEXX) - Price-to-Revenue Ratio|Market Cap to Revenue Pheton Holdings|Price-to-Revenue Ratio Aptorum Group Ltd|Lyra Therapeutics Inc. - Price-to-Sales Ratio|P/S Multiple IBO|TNFA (tnfpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple YCBD (cbdMD)|P/S Multiple painreform.com PRFX|CYTO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio LIPO (Lipella Pharmaceuticals Inc)|Optinose (OPTN) - Price-to-Revenue Ratio|Market Cap to Revenue Pieris Pharma|PROC (Procaps Group S.A.) - P/S Multiple|P/S Multiple petrospharma.com|Market Cap to Revenue QLI (Qilian International Holding)|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TFF Pharma TFFP